Regine Brox

Regine Brox

Auto-generated profile, based on publicly available information

Regine Brox

Department of Transfusion Medicine and Hemostaseology, University Hospital Erlangen, Erlangen, Germany, fau.eu

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LWLukas Waterloo
Lukas Waterloo
HHHarald Hübner
Harald Hübner
FFFabrizio Fierro
Fabrizio Fierro
TPTara Pfeiffer
Tara Pfeiffer
RBRegine Brox
Regine Brox
PGPeter Gmeiner
Peter Gmeiner


24 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RBRegine Brox
Regine Brox
HHHolger Hackstein
Holger Hackstein
Acetylsalicylic acid is a globally used non-steroidal anti-inflammatory drug (NSAID) with diverse pharmacological properties, although its mechanism of immune regulation during inflammation (especially atin vivorelevant doses) remains largely speculative. Given the increase in clinical perspective of Acetylsalicylic acid in various diseases and cancer prevention, this study aimed to investigate the immunomodulatory role of physiological Acetylsalicylic acid concentrations (0.005, 0.02 and 0.2 mg/ml) in a human whole blood of infection-induced inflammation. We describe a simple, highly reliable whole blood assay using an array of toll-like receptor (TLR) ligands 1–9 in order to systematically explore the immunomodulatory activity of Acetylsalicylic acid plasma concentrations in physiologically relevant conditions. Release of inflammatory cytokines and production of prostaglandin E2(PGE2) were determined directly in plasma supernatant. Experiments demonstrate for the first time that plasma concentrations of Acetylsalicylic acid significantly increased TLR ligand-triggered IL-1β, IL-10, and IL-6 production in a dose-dependent manner. In contrast, indomethacin did not exhibit this capacity, whereas cyclooxygenase (COX)-2 selective NSAID, celecoxib, induced a similar pattern like Acetylsalicylic acid, suggesting a possible relevance of COX-2. Accordingly, we found that exogenous addition of COX downstream product, PGE2, attenuates the TLR ligand-mediated cytokine secretion by augmenting production of anti-inflammatory cytokines and inhibiting release of pro-inflammatory cytokines. Low PGE2levels were at least involved in the enhanced IL-1β production by Acetylsalicylic acid.

15 September 2021 in Nanomedicine
Verified
Journal Article
Closed access
LPLennart Pusch
Lennart Pusch
RBRegine Brox
Regine Brox
KSKarl Scheuer
Karl Scheuer
TYTadahiro Yokosawa
Tadahiro Yokosawa
MWMingjian Wu
Mingjian Wu
HHHolger Hackstein
Holger Hackstein
Background: Poly(lactic-co-glycolic) acid (PLGA) nanoparticles can be prepared by emulsion-solvent-evaporation from o/w and w1/o/w2 emulsions. Aims: To elaborate similarities and differences regard...

8 October 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
RBRegine Brox
Regine Brox
SASusanne Achenbach
Susanne Achenbach
HHHolger Hackstein
Holger Hackstein
Background: Convalescent plasma has emerged as a potential specific treatment for coronavirus disease 2019 (COVID‐19), since it contains severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies. Several studies are currently investigating the efficacy of convalescent plasma for treatment of COVID‐19, with a focus on neutralizing antibodies. However, there is little information on whether convalescent plasma may contain additional immunoregulatory constituents produced by the blood donor during convalescence. Therefore, using a standardized whole blood assay employing synthetic toll‐like receptor (TLR) ligands, we have investigated the immunoregulatory capacity of convalescent plasma in direct comparison to ABO‐matched allogeneic control plasma.Study design and methods: Whole blood samples from healthy blood donors were collected, and autologous plasma was replaced by convalescent plasma or ABO‐matched control plasma. Standardized innate immune triggering and monitoring was performed by adding different TLR ligands (Pam3CsK4 [TLR1/2], HKLM [TLR2], LPS [TLR4], flagellin [TLR5], ssRNA40 [TLR8], imiquimod [TLR7], and FSL‐1 [TLR2/6]) and subsequent quantitative analysis of pro‐ and anti‐inflammatory cytokines (IP‐10, IL‐1β, TNF‐α, MCP‐1, IL‐6, IL‐10, and IFN‐γ) by cytometric bead array. Negative controls included unstimulated samples as well as samples spiked with autologous plasma.Results: COVID‐19 convalescent plasma (CCP) significantly decreased pro‐inflammatory cytokines production triggered by different TLR ligands in healthy donors as compared with healthy control plasma. IL‐6, MCP‐1, and IFN‐γ represented the cytokines that are most frequently downregulated by convalescent plasma.Conclusion: Our experiments reveal a potential novel, SARS‐CoV‐2‐independent immunomodulatory activity of CCP, which may be beneficial for COVID‐19 patients.

15 March 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LPLennart Pusch
Lennart Pusch
RBRegine Brox
Regine Brox
SCSarah Cunningham
Sarah Cunningham
DFDagmar Fischer
Dagmar Fischer
HHHolger Hackstein
Holger Hackstein